Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.

Abstract:

:The optimal pharmacological therapy of community-acquired pneumonia (CAP) is one of the most ardently debated issues in medicine. Presently, most guidelines recommend either a fluoroquinolone alone or dual therapy with a third-generation cephalosporin plus a macrolide in patients hospitalised with CAP, but few provide clinicians with specific considerations for selecting from these agents. Despite a similar spectrum of activity and favourable resistance patterns (for fluoroquinolones and third-generation cephalosporins) against CAP pathogens, there is emerging evidence that dual therapy may be superior to monotherapy in certain populations.In patients with non-severe CAP, the evidence supports the use of either monotherapy or dual therapy in most patients; however, patients with severe CAP or bacteraemic pneumococcal CAP experience improved survival when treated with dual therapy. It is unclear from this evidence if any specific combination of agents is the most effective, but the combination of a third-generation cephalosporin plus a macrolide is the most extensively studied. Dual therapy was superior to monotherapy irrespective of the susceptibility of the aetiological pathogen, thus insufficient antimicrobial spectrum does not explain the disparity. The most likely explanation for improved outcomes with dual therapy is the combined effect of optimised antimicrobial spectrum (including atypicals), decreased impact of resistance to a single agent and the immunomodulatory effects of macrolides. Increasing resistance in patients with non-severe CAP warrants the consideration of dual therapy and perhaps a reappraisal of agents usually reserved for second-line therapy, including doxycycline, in these populations as well. In light of the available evidence, dual therapy should be strongly considered in all patients with severe CAP, especially when complicated by pneumococcal bacteraemia.

journal_name

Drugs

journal_title

Drugs

authors

Epstein BJ,Gums JG

doi

10.2165/00003495-200565140-00004

subject

Has Abstract

pub_date

2005-01-01 00:00:00

pages

1949-71

issue

14

eissn

0012-6667

issn

1179-1950

pii

65144

journal_volume

65

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Clinical potential of topical corticosteroids.

    abstract::The treatment of a variety of inflammatory skin diseases was greatly changed by the introduction, in the early 1950s, of corticosteroids for topical use. Topical corticosteroids are still the most widely used drugs in dermatology, and many preparations with quite different potencies are now available. However, attempt...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198800365-00008

    authors: Ortonne JP

    更新日期:1988-01-01 00:00:00

  • Quinidine and digoxin. An important interaction.

    abstract::An increase in serum digoxin concentration occurs in 90% of patients given quinidine. On average, the serum digoxin doubles during treatment with therapeutic doses of quinidine. Almost every patient treated with quinidine will have a decrease in the renal clearance of digoxin and many will have a decrease in the volum...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198224030-00003

    authors: Bigger JT Jr,Leahey EB Jr

    更新日期:1982-09-01 00:00:00

  • Effects of alpha-adrenoceptor blockers on renal function and blood pressure adjustment in human hypertension.

    abstract::In this paper the different aspects of the role played by alpha-adrenoceptors in the control of renin secretion from the juxtaglomerular apparatus and renal sodium and water reabsorption, and the effects of alpha-adrenoceptor antagonists on systemic haemodynamics, will be investigated. Animal experiments suggest that ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198800356-00007

    authors: Leonetti G

    更新日期:1988-01-01 00:00:00

  • Panic disorder. Pathophysiology and drug treatment.

    abstract::Advances over the past 2 decades in our understanding of the biology of panic disorder have paralleled a remarkable increase in the development of new pharmacological agents with antipanic effects. Although we can not presently use biological tests to help with our choice of therapeutic agent for individual patients, ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549030-00002

    authors: Johnson MR,Lydiard RB,Ballenger JC

    更新日期:1995-03-01 00:00:00

  • HDL-cholesterol as a risk factor in coronary heart disease. An update of the Helsinki Heart Study.

    abstract::The aim of the Helsinki Heart Study, a 5-year primary prevention placebo-controlled study involving 4081 dyslipidaemic men (aged 40 to 55 years), was to investigate if increasing high density lipoprotein (HDL)-cholesterol plasma levels and decreasing low density lipoprotein (LDL)-cholesterol levels would reduce the in...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199000401-00004

    authors: Frick MH,Manninen V,Huttunen JK,Heinonen OP,Tenkanen L,Mänttäri M

    更新日期:1990-01-01 00:00:00

  • Brodalumab: First Global Approval.

    abstract::Brodalumab (Lumicef(®)) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Brodalumab binds with high affinity to interleukin (IL)-...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-016-0634-8

    authors: Greig SL

    更新日期:2016-09-01 00:00:00

  • Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.

    abstract::Although antiangiogenic treatments have produced milestone advances in the treatment of several diseases, and have significantly extended the median survival of cancer patients, these agents share some weaknesses, including a limited impact on the overall cure rate, a fleeting effect because of redundant pathways or e...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0154-8

    authors: Aprile G,Bonotto M,Ongaro E,Pozzo C,Giuliani F

    更新日期:2013-12-01 00:00:00

  • Gatifloxacin: a review of its use in the management of bacterial infections.

    abstract:UNLABELLED:Gatifloxacin is an 8-methoxy fluoroquinolone antibacterial agent. The drug has a broader spectrum of antibacterial activity than the older fluoroquinolones (e.g. ciprofloxacin) and shows good activity against many Gram-positive and Gram-negative pathogens, atypical organisms and some anaerobes. Notably, gati...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262010-00007

    authors: Perry CM,Ormrod D,Hurst M,Onrust SV

    更新日期:2002-01-01 00:00:00

  • Management of chronic obstructive pulmonary disease.

    abstract::Chronic obstructive pulmonary disease (COPD) is characterised by insidiously progressive airflow limitation. The necessarily multifactorial management programme should include smoking cessation, prevention of infections, bronchodilator and steroid therapy, supplemental oxygen, physical therapy, pulmonary rehabilitatio...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-198938010-00007

    authors: Kesten S,Rebuck AS

    更新日期:1989-07-01 00:00:00

  • Potential of aromatase inhibitors for ovulation and superovulation induction in infertile women.

    abstract::For almost half a century, the first-line treatment for ovulation induction in cases of anovulation, unexplained infertility, or mild male factor has been clomifene (clomiphene citrate). Clomifene is an effective and safely used oral agent, but is known to have relatively common antiestrogenic endometrial and cervical...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666170-00001

    authors: Mitwally MF,Casper RF

    更新日期:2006-01-01 00:00:00

  • Prediction of response to cancer chemotherapy.

    abstract::Cytotoxic chemotherapy plays a key role in the treatment of carcinoma for thousands of patients annually who either present with metastatic disease or relapse after surgical excision of apparently localised disease. Unfortunately, there is such a wide range of responsiveness to drug therapy within individual tumour ty...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198326050-00004

    authors: Sarosdy MF,Von Hoff DD

    更新日期:1983-11-01 00:00:00

  • Dual inhibitory action of nedocromil sodium on antigen-induced inflammation.

    abstract::In human lung tissue in vitro, nedocromil sodium inhibited the release of histamine and leukotrienes induced by anti-IgE, as well as the contraction of isolated bronchi which followed this challenge. In the hamster cheek pouch in vivo, nedocromil sodium inhibited the inflammatory response induced by challenge with eit...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198900371-00013

    authors: Dahlén SE,Björck T,Kumlin M,Sydbom A,Raud J,Palmertz U,Franzén L,Grönneberg R,Hedqvist P

    更新日期:1989-01-01 00:00:00

  • Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.

    abstract::Osteoporosis is a systemic bone disease characterized by low bone mass and bone mineral density, and deterioration of the underlying structure of bone tissue. These changes lead to an increase in bone fragility and an increased risk for fracture, which are the clinical consequences of osteoporosis. The classical triad...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11587570-000000000-00000

    authors: Reginster JY

    更新日期:2011-01-01 00:00:00

  • Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.

    abstract::Vemurafenib is the first molecularly targeted therapy to be licensed in the US and Europe for treatment of advanced melanoma. Its mechanism of action involves selective inhibition of the mutated BRAF V600E kinase that leads to reduced signalling through the aberrant mitogen-activated protein kinase (MAPK) pathway. Its...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11640870-000000000-00000

    authors: Sharma A,Shah SR,Illum H,Dowell J

    更新日期:2012-12-03 00:00:00

  • Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.

    abstract::Benzbromarone1 is a benzofuran derivative which lowers serum urate and increases urinary urate excretion in normal, hyperuricaemic and gouty subjects. In open short- and long-term studies benzbromarone reduced serum uric acid levels by one-third to one-half and maintained its effectiveness for periods of up to 8 years...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197714050-00002

    authors: Heel RC,Brogden RN,Speight TM,Avery GS

    更新日期:1977-11-01 00:00:00

  • Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

    abstract::Endothelial dysfunction and increased arterial stiffness occur early in the pathogenesis of diabetic vasculopathy. They are both powerful independent predictors of cardiovascular risk. Advances in non-invasive methodologies have led to widespread clinical investigation of these abnormalities in diabetes mellitus, gene...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565010-00003

    authors: Woodman RJ,Chew GT,Watts GF

    更新日期:2005-01-01 00:00:00

  • Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.

    abstract::Certolizumab pegol (Cimzia(®)) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor (TNF)-α. The drug is indicated for subcutaneous use every 2 or 4 weeks (q2w or q4w) for the treatment of adults with mo...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0009-3

    authors: Deeks ED

    更新日期:2013-01-01 00:00:00

  • The role of proton pump inhibitors in gastro-oesophageal reflux disease.

    abstract::The proton pump inhibitors (PPIs) are the most successful class of drugs that have been introduced for the treatment of gastro-oesophageal reflux disease (GORD) because of their profound and consistent effect on gastric acid secretion. The PPIs have demonstrated an excellent adverse effect profile after approximately ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464030-00004

    authors: Dekel R,Morse C,Fass R

    更新日期:2004-01-01 00:00:00

  • Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.

    abstract::86 patients with a first myocardial infarction presenting within 6 hours of the onset of symptoms were randomly allocated to treatment with intravenous streptokinase or anisoylated plasminogen streptokinase activator complex (APSAC). Plasma concentrations of fibrinogen, plasminogen, alpha 2-antiplasmin and fibrinogen ...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198700333-00046

    authors: Monassier JP,Hanssen M

    更新日期:1987-01-01 00:00:00

  • Management of vasodilatory shock: defining the role of arginine vasopressin.

    abstract::The rationale for an arginine vasopressin (argipressin) infusion was put forward after it was discovered that patients in shock states might have an endogenous arginine vasopressin deficiency. Subsequently, several investigations impressively demonstrated that arginine vasopressin can successfully stabilise haemodynam...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363030-00001

    authors: Dunser MW,Wenzel V,Mayr AJ,Hasibeder WR

    更新日期:2003-01-01 00:00:00

  • Aspirin-induced asthma: clinical aspects, pathogenesis and management.

    abstract::Aspirin (acetylsalicylic acid)-induced asthma (AIA) consists of the clinical triad of asthma, chronic rhinosinusitis with nasal polyps, and precipitation of asthma and rhinitis attacks in response to aspirin and other NSAIDs. The prevalence of the syndrome in the adult asthmatic populations is approximately 4-10%. Res...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464210-00004

    authors: Hamad AM,Sutcliffe AM,Knox AJ

    更新日期:2004-01-01 00:00:00

  • The sore throat. When to investigate and when to prescribe.

    abstract::Sore throats are most commonly due to infections, many of which are viral and do not require specific treatment. Symptoms and signs of the common cold, influenza or croup, the occurrence of conjunctivitis in some adenoviral infections, generalised lymphadenopathy and splenomegaly in glandular fever or the presence of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199040060-00007

    authors: Lang SD,Singh K

    更新日期:1990-12-01 00:00:00

  • Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.

    abstract::Many drugs alter the anticoagulant effect of oral coumarins. It is essential that physicians be aware of interactions leading to increased or decreased anticoagulation or to erratic control. Interacting drugs can be classified as influencing the pharmacodynamics (pharmacological actions) or the pharmacokinetics (absor...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197611060-00006

    authors: MacLeod SM,Sellers EM

    更新日期:1976-01-01 00:00:00

  • Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus?

    abstract::Results from the United Kingdom Prospective Diabetes Study showed that intensive treatment of type 2 (non-insulin-dependent) diabetes mellitus, with sulphonylureas or insulin, significantly reduced microvascular complications but did not have a significant effect on macrovascular complications after 10 years. Insulin ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060050-00004

    authors: Campbell IW

    更新日期:2000-11-01 00:00:00

  • Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.

    abstract::Bisoprolol is a beta 1-adrenoceptor antagonist with no partial agonist (intrinsic sympathomimetic) activity or membrane stabilising (local anaesthetic) activity. The oral bioavailability of bisoprolol is high (90%) and the drug has a long elimination half-life which allows once-daily administration; in addition, it is...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198836030-00002

    authors: Lancaster SG,Sorkin EM

    更新日期:1988-09-01 00:00:00

  • Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.

    abstract:UNLABELLED:Oxaliplatin is a platinum compound that inhibits DNA synthesis, primarily by causing intrastrand cross-links in DNA. Oxaliplatin has a broad spectrum of antineoplastic activity and has demonstrated a lack of cross-resistance with other platinum compounds. In patients with metastatic colorectal cancer, intrav...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060040-00005

    authors: Culy CR,Clemett D,Wiseman LR

    更新日期:2000-10-01 00:00:00

  • Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.

    abstract::Several large-scale clinical trials have assessed the efficacy of atorvastatin in the primary and secondary prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. In primary prevention, CARDS (Collaborative Atorvastatin Diabetes Study) showed that atorvastatin 10 mg/day (vs p...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767001-00005

    authors: Arca M

    更新日期:2007-01-01 00:00:00

  • Drug-resistant tuberculosis: what are the treatment options?

    abstract::Drug-resistant tuberculosis (DR-TB) is an emerging global health threat as treatment involves complex multiple drug regimens, which are longer and more toxic than standard therapy and yet have worse outcomes. In the presence of resistance to one or more first-line drugs, an alternative regimen should be designed. A ma...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11585440-000000000-00000

    authors: Albanna AS,Menzies D

    更新日期:2011-05-07 00:00:00

  • European Surveillance of Antimicrobial Consumption (ESAC): value of a point-prevalence survey of antimicrobial use across Europe.

    abstract::All 27 EU member states and another seven countries participate in the European Surveillance of Antimicrobial Consumption (ESAC) project. ESAC carried out three hospital point-prevalence surveys on antimicrobial use. Point-prevalence surveys linked antimicrobial use to indication and also assessed dosing using a stand...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11591180-000000000-00000

    authors: Zarb P,Goossens H

    更新日期:2011-04-16 00:00:00

  • Valdecoxib.

    abstract::In ten large, well-controlled, randomised trials (n = 203 to 1089), valdecoxib, a selective inhibitor of cyclo-oxygenase-2, was significantly more effective than placebo in the treatment of osteoarthritis, rheumatoid arthritis and pain associated with primary dysmenorrhoea, and for postsurgical analgesia. Valdecoxib 1...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262140-00005

    authors: Ormrod D,Wellington K,Wagstaff AJ

    更新日期:2002-01-01 00:00:00